Glanzmann's disease
Definition
Glanzmann's disease is a rare disorder of blood platelets, which results in easy bruising and nosebleeds.
Alternative Names
Thrombasthenia
Causes
Glanzmann's disease is caused by lack of a protein required for platelets to clump together (aggregate) normally.
The condition is congenital, which means it is present from birth.
Symptoms
- Abnormal menstrual periods
- Bleeding during and after surgery
- Bleeding gums
- Easy bruising
- Nosebleeds (epistaxis)
- Prolonged bleeding with small injuries
Exams and Tests
The following tests may be used to diagnose this condition:
- Complete blood count (CBC)
- Bleeding time
- Platelet aggregation tests
- Prothrombin time (PT) and partial thromboplastin time (PTT)
Other tests may be necessary, including the testing of relatives.
Treatment
There is no specific treatment for this disorder. Platelet transfusions may be given to patients who are having severe bleeding.
Outlook (Prognosis)
Glanzmann's thrombasthenia is a lifelong condition for which there is no cure. Patients should take precautions to avoid bleeding.
Anyone with a bleeding disorder should avoid taking aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen because these drugs can prolong bleeding times.
Possible Complications
- Severe bleeding
- Iron deficiency anemia in menstruating women
When to Contact a Medical Professional
Call your health care provider if bleeding or bruising of an unknown cause is present, or if bleeding does not stop after usual treatments.
Prevention
A blood test can detect the gene responsible for the condition.
Genetic counseling may be helpful to couples with a family history of platelet disorders who are planning to have children in the future.
McMillan R. Hemorrhagic disorders: Abnormalities of platelet and vascular function. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 179.
Reviewed By: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
